Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7198457 plus atezolizumab versus atezolizumab in ctDNA-positive stage II–III NSCLC after surgery and adjuvant chemotherapy
2019-003449-14Phase 2Unknown
- Sponsor
- Genentech
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing RO7198457 plus atezolizumab with Atezolizumab alone (2 arms). Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
autogene cevumeranatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-003449-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003449-14.